Recent Finacing
Recent Raise
Convergent Therapeutics is a Cambridge, MA clinical-stage biotech developing tumor-selective alpha radioantibodies, including CONV01-α — an Ac-225–conjugated PSMA antibody in Phase II trials for PSMA PET–positive mCRPC.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Convergent Therapeutics.
